G&E Herbal Biotechnology Co., Ltd.

4911 · TWO · Healthcare / Biotechnology

25.55TWD-0.40 (-1.54%)

Price History

Full chart

Market Stats

Previous Close25.95

Open25.05

Day Range25.00 – 25.55

52-Week Range27.18 – 44.82

Volume15.94K

Market Cap1.95B

P/E (TTM)22.72

Forward P/E0.00

EPS1.25

Dividend Yield4.11%

Beta-0.73

50-Day Avg28.96

200-Day Avg32.28

About

G&E Herbal Biotechnology Co., Ltd. engages in manufacturing and wholesale of western and chinese medicine, cosmetics, intellectual property rights, biotechnology services, medical device, and other unclassified food products in Taiwan. It offers HepaGent capsules, a liver protective agent; botanical food supplements; botanical anti-aging cosmetics, such as facial cleansing essence, botanic extract toner, moisturizing cream and serum, and essential oil; smile cream and topical gel; as well as lubricants. G&E Herbal Biotechnology Co., Ltd. was founded in 2002 and is based in Tainan City, Taiwan.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Kou-Wha Kou Ph.D.
Employees43
HeadquartersNo.92, Keji 5th Road, Tainan City, Taiwan, 709015, Taiwan
Websitehttps://www.geherbs.com.tw

Leadership

Mr. Kou-Wha Kou Ph.D.CEO of R&D Department, CEO & Chairman
Mr. Zhang Yi HongFinance Manager
Ms. Xuan Xuan LinMarketing Director
Mr. Bing Yuan ChenProduction Manager
Ms. Wei Min HongManager of Quality Department
Zhangyi HongAccounting Supervisor
Mr. Sheng Hui ZhouAudit Office Manager

Financials

Income Statement

Currency: TWD	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	24.57M	64.61M	181.44M	249.03M	309.13M
Growth (%)	-	+162.94%	+180.84%	+37.25%	+24.13%
Cost of Revenue	14.95M	25.25M	36.86M	43.69M	45.91M
Gross Profit	9.63M	39.35M	144.59M	205.34M	263.22M
Gross Margin	39.17%	60.91%	79.69%	82.46%	85.15%
Operating Expense	29.18M	33.87M	63.90M	85.70M	110.92M
Operating Income	-19.56M	5.49M	80.68M	119.65M	152.30M
Operating Margin	-79.61%	8.49%	44.47%	48.04%	49.27%
EBITDA	-	16.63M	99.84M	135.15M	169.03M
EBITDA Margin	-	25.73%	55.02%	54.27%	54.68%
Net Income	-19.88M	7.38M	72.40M	102.06M	139.20M
Net Income Margin	-80.92%	11.42%	39.90%	40.98%	45.03%
R&D	12.54M	14.39M	24.60M	35.34M	34.89M
R&D as % of Total Revenue	51.03%	22.27%	13.56%	14.19%	11.29%
Interest Expense	-	0	4.00K	41.00K	29.00K
Interest Expense % of Total Revenue	-	0.00%	0.00%	0.02%	0.01%

Balance Sheet

Currency: TWD	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	692.13M	782.77M	883.10M	959.17M	975.22M
Total Liabilities	8.68M	91.94M	119.86M	125.64M	47.15M
Total Equity	683.45M	690.84M	763.24M	833.53M	928.07M
Cash	12.28M	114.75M	139.68M	152.59M	78.41M

Cash Flow

Currency: TWD	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-9.19M	99.96M	113.48M	134.68M	70.18M
Capital Expenditure	1.99M	2.97M	5.52M	6.00M	3.20M
Free Cash Flow	-11.18M	97.00M	107.96M	128.68M	66.97M
Dividends Paid	-	-	-	31.76M	44.66M
FCF to OCF	121.62%	97.03%	95.14%	95.54%	95.44%
Dividend Paid to FCF	-	-	-	24.69%	66.68%

Earnings

Report Date	Apr 8, 2011	Oct 26, 2012	Aug 11, 2013	May 11, 2014	Aug 6, 2014
EPS Estimate	0.04	-0.04	-0.02	0.13	0.15
EPS Actual	-0.11	-0.01	-0.03	0.06	0.04
Surprise	-375.00%	75.00%	-50.00%	-53.85%	-73.33%
Timing	After-hours	After-hours	After-hours	After-hours	Pre-market

Key Statistics & Ratios

Market Cap1.95B

Enterprise Value1.57B

Trailing P/E22.72

Forward P/E0.00

Price / Sales9.06

Price / Book2.27

EPS1.25

Book Value12.74

Revenue (TTM)215.61M

Gross Profit (TTM)173.54M

EBITDA92.72M

Profit Margin40.00%

Operating Margin22.98%

Return on Equity9.91%

Return on Assets5.21%

Shares Outstanding68.82M

Shares Float51.39M

Beta-0.73

Dividend Yield4.11%

Dividend Rate1.17

Payout Ratio56.11%

Dividends

20261×

1.17Jul 28, 2026

20251×

0.70Jul 29, 2025

20241×

0.49Aug 20, 2024

20151×

0.08Aug 25, 2015

Stock Splits

Jul 28, 20261080:1000
Jul 29, 20251080:1000
Aug 20, 20241060:1000
Aug 25, 20151012:1000